TheraRadar
Data updated: May 26, 2026

DEPEN (penicillamine)

Immunology Approved 1978-11-08

DEPEN is indicated for the treatment of Wilson’s Disease; Cystinuria; Rheumatoid Arthritis.

Source: FDA Label • Viatris
1
Indication
--
Phase 3 Trials
47
Years on Market

Details

Status
Prescription
First Approved
1978-11-08
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: PENICILLAMINE

DEPEN Approval History

1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 1978 to 1994
Aug 1994 SUPPL
Mfg · Manufacturing (CMC)
Oct 1993 SUPPL
Mfg · Manufacturing (CMC)
Jun 1990 SUPPL
Mfg · Manufacturing (CMC)

What DEPEN Treats

3 indications

DEPEN is approved for 3 conditions since its original approval in 1978. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Wilson’s Disease
  • Cystinuria
  • Rheumatoid Arthritis
Source: FDA Label

DEPEN Boxed Warning

Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity....

DEPEN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DEPEN

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

SYPRINE
TRIENTINE HYDROCHLORIDE
3 shared
BAUSCH
Shared indications:
Wilson’s DiseaseCystinuriaRheumatoid Arthritis
PENICILLAMINE
PENICILLAMINE
2 shared
INVAGEN PHARMS
Shared indications:
ABRILADA
ADALIMUMAB-AFZB
1 shared
Pfizer
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEPEN FDA Label Details

Indications & Usage

DEPEN is indicated for the treatment of Wilson’s Disease; Cystinuria; Rheumatoid Arthritis.

⚠️ BOXED WARNING

Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients shou...

Track DEPEN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.